Antagonism of Na(v) channels and α(1)-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine

Ranolazine is a recently developed drug used for the treatment of patients with chronic stable angina. It is a selective inhibitor of the persistent cardiac Na(+) current (I(Na)), and is known to reduce the Na(+)-dependent Ca(2+) overload that occurs in cardiomyocytes during ischemia. Vascular effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Virsolvy, Anne, Farah, Charlotte, Pertuit, Nolwenn, Kong, Lingyan, Lacampagne, Alain, Reboul, Cyril, Aimond, Franck, Richard, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674695/
https://www.ncbi.nlm.nih.gov/pubmed/26655634
http://dx.doi.org/10.1038/srep17969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674695/
https://www.ncbi.nlm.nih.gov/pubmed/26655634
http://dx.doi.org/10.1038/srep17969

Ejemplares similares